Share on StockTwits

Shares of Sinclair IS Pharma PLC (LON:SPH) have earned an average recommendation of “Buy” from the eight analysts that are currently covering the company, Analyst RN reports. Two analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is GBX 37.13 ($0.64).

A number of analysts have recently weighed in on SPH shares. Analysts at Canaccord Genuity raised their price target on shares of Sinclair IS Pharma PLC from GBX 38 ($0.65) to GBX 44 ($0.75) in a research note on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at N+1 Singer reiterated a “buy” rating on shares of Sinclair IS Pharma PLC in a research note on Tuesday. They now have a GBX 40 ($0.68) price target on the stock. Finally, analysts at FinnCap reiterated a “buy” rating on shares of Sinclair IS Pharma PLC in a research note on Tuesday. They now have a GBX 43 ($0.74) price target on the stock.

Shares of Sinclair IS Pharma PLC (LON:SPH) traded down 0.45% on Tuesday, hitting GBX 30.3625. The stock had a trading volume of 179,916 shares. Sinclair IS Pharma PLC has a one year low of GBX 23.50 and a one year high of GBX 34.18. The stock’s 50-day moving average is GBX 30.83 and its 200-day moving average is GBX 30.79.

Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.